Shiuan Chen, Ph.D.
Ph.D., Biochemistry, University of Hawaii, Honolulu, Hawaii
B.S., Chemistry, National Taiwan College of Marine Science and Technology, Keelung Taiwan, Republic of China
2022-present, Professor and Chair, Department of Cancer Biology and Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA.
2012-2022, Professor and Chair, Department of Cancer Biology, Beckman Research Institute of City of Hope, Duarte, CA
2009-2012, Professor and Director, Division of Tumor Cell Biology, Beckman Research Institute of City of Hope, Duarte, CA
2009-2012, Professor and Associate Chair, Department of Cancer Biology, Beckman Research Institute of City of Hope, Duarte, CA
2002-2009, Professor and Director, Division of Tumor Cell Biology, Department of Surgery, City of Hope, Duarte, CA
1994-2002, Professor, Department of Immunology, Beckman Research Institute of City of Hope, Duarte, CA
1988-1994, Associate Research Scientist, Department of Immunology, Beckman Research Institute of City of Hope, Duarte, CA
1985-1988, Assistant Research Scientist, Department of Immunology, Beckman Research Institute of City of Hope, Duarte, CA
1982-1985, Research Assistant Professor, School of Pharmacy, University of Southern California, Los Angeles, CA
1981-1982, Assistant Researcher, Department of Biochemistry and Biophysics, University of Hawaii
1978-1981, Junior Researcher, Department of Biochemistry and Biophysics, University of Hawaii
Breast Cancer Translation Research
Shiuan Chen, Ph.D., was one of the three investigators who originally isolated full-length human aromatase cDNA clones. He has a long-standing interest in the response of and resistance to hormone-directed therapies for breast cancer. The Chen laboratory characterized a collection of ER+ or AR+ PDX models (Kanaya, et al., 2016). Several projects have been developed using these PDX lines, including biomarker analysis of estrogen-stimulated and –suppressed ER+ PDXs, molecular characterization of AR+ triple-negative breast cancers, and drug responses of ER+/HER2+ cancers (Petrossian, et al., 2018; Yamamoto, et al., 2019; Kanaya, et al., 2019; Wang Y, et al., 2020; Wang Y, et al., 2020; Wang X, et al., 2021a; Wang X, et al., 2021b; Wang Y and Chen, 2021; Mori, et al., 2021).
Single cell RNA sequencing (scRNAseq) is a powerful technique that generates high resolution gene expression information at the individual cell level, allowing the characterization of heterogenous cell populations and complex cellular networks among different cell types. Such information cannot be obtained from bulk RNA sequencing. In 2021, we published one single-cell paper linking mouse mammary gland development to breast carcinogenesis in woman (Saeki, et al., 2021). We generated a comprehensive mammary cell gene expression atlas with results from mouse mammary gland at most lifetime stages. The atlas was able to infer cells of origin of human breast cancer subtypes. As a nonbiased approach, we hypothesize that scRNAseq will be very useful to determine cellular features of ER+ and ER- cells in luminal cancers and possible gene expression changes/interaction among these cells under estrogen manipulation. For the first time, our single cell analysis (Mori, et al., 2021) has revealed that estrogen affects ESR1- cells in ER+ breast cancer, explaining why a 100% ER positivity is not required for an endocrine response. In a recent publication by Yoshitake, et al. (2022), we characterized mouse mammary fibroblasts with distinct functions, estrogen responses, differentiation processes, and crosstalks with epithelium.
Spatial transcriptomics is a novel approach to spatially-resolve whole transcriptome mRNA expression, while capturing histological information in the same tissue section. Such a study will provide a comprehensive view of tissue complexity by mapping where all gene activity is occurring and discover novel targets with unbiased analyses. We have initiated a project to define different functions of cell clusters in ER+ breast cancer.
Lisa Yee, M.D., and Dr. Chen have initiated a new Phase 1 trial on the effect of mushroom on breast cancer prevention in high-risk women (NCT04913064).
Prostate Cancer Translation Research
Dr. Chen has an extensive interest in the development of natural products as alternatives to and in conjunction with conventional Western medicines, including the potential role of plant-derived phytochemicals in prostate cancer prevention, risk of recurrence, and therapy. Based on earlier work in his laboratory, Dr. Chen, Przemyslaw Twardowski, M.D., Paul Frankel, Ph.D., Timothy Synold, Pharm.D., and Sumanta Pal, M.D., conducted a Phase 1 trial of white button mushroom (WBM) powder in patients with biochemically recurrent prostate cancer, examining the effects of WBM powder on serum PSA levels and determined the tolerability and biological activity of WBM (NCT00779168). Two patients experienced complete responses (CR; decline in PSA to undetectable levels) and two patients experienced partial responses (PR). Patients with CR and PR demonstrated higher levels of baseline interleukin-15 than non-responders, and this group had therapy-associated declines in myeloid-derived suppressor cells (MDSCs) (Twardowski, et al., 2015). A reverse translational research is initiated to examine the effect of mushroom intake on MDSC levels in mice. With a grant from NIH in 2019 (R01 CA227230), the team (Chen, Twardowski, Lau, Frankel, and Synold) has started a Phase 2 trial to verify the finding from the first trial. We have received the approval of IND (from FDA) and IRB. The phase 2 trial was initiated in May 2021 (NCT04519879). Recently, we have published one paper to explain the anti-AR activity of mushroom chemicals (Wang X, et al., 2021a).
A proof-of-concept preclinical study has been completed to demonstrate that mushroom intake may slow down the COVID-19 infection through immune modulation. A paper to report these findings was published (Wang X, et al., 2021b).
Endocrine Disruptor Research
Our group is evaluating the impact of endocrine disrupting chemicals (EDCs) on the risk of breast cancer. EDCs may promote the development of breast cancer by interacting with aromatase (i.e. estrogen synthetase), estrogen receptor-α (ERα), estrogen receptor-β (ERβ), and/or progesterone receptor (PR). As EDC exposure events typically involve complex mixtures, Dr. Chen has developed a functional assay to determine the overall estrogenic and anti-aromatase activity of serum samples, the AroER tri-screen (Kanaya, et al., 2015). This high throughput screening system not only bypasses the need for single chemical measurements but also circumvents difficulties with isolating and defining post-exposure interactions between the EDCs and endogenous steroid hormones through conventional approaches. The screen has been used to identify potential aromatase inhibitors (AIs) in the U.S. Tox21 10K compound library (Chen, S. et al., 2015); ten AI-like compounds were identified, including the irreversible, long-lasting and potent anti-aromatase activity of imazalil, a fungicide widely used in agriculture. Such findings suggest that AroER tri-screen can screen and quantify unexpected or uncharacterized exposures to chemicals that interact with aromatase, ER, and PR during breast cancer development (Kanaya, et al., 2019; Bahrami, 2020). A collaboration between Dr. Chen and Lisa Yee, M.D., has been initiated to investigate the effects of aromatase inhibitor and natural product intake in high risk (for breast cancer) women by examining the changes of estrogen/androgen levels through AroER tri-screen assay.
Dr. Chen and Susan Neuhausen, Ph.D., The Morris & Horowitz Families Professor in Cancer Etiology & Outcomes Research, have investigated the impact of exposure to EDCs on the risk of breast cancer development during an important period of susceptibility, the menopausal transition. According to the Women’s Health Initiative (WHI), hormone therapy during this period increased both the incidence of and mortality from breast cancer. To investigate whether EDCs mimic this therapy and also promote the development of breast cancer during the menopausal transition, the team has interrogated two EDCs that have been recognized as major health concerns: polybrominated diphenyl ethers (PBDEs) and bisphenol A (BPA), a commonly used component in food-grade plastics. A transdisciplinary approach included cell culture, mouse models, and samples collected from women during the menopausal transition. The approach involved our AroER-Tri screen to interrogate EDC mechanisms; determined the effects of EDCs in women during menopausal transition on the estrogenic activity and the epigenome; and tested the effects of EDCs on the development of mammary lesions in a mouse model of menopause. In addition, with their community partners, the team has also provided a web-based resource on the role of exposures on development of breast cancer.
We have studied the combined action of estrogen and polybrominated diphenyl ethers (PBDEs) in mammary gland through scRNAseq approach (Kanaya, et al., 2019) and reviewed the importance of this technique in the field of environmental carcinogenesis (Chang, et al., 2020).
David Sadava, Ph.D.
626-256-HOPE, ext. 86062
Xiaoqiang Wang, Ph.D.
626-256-HOPE, ext. 83056
Ryohei Yoshitake, Ph.D.
626-256-HOPE, ext. 86062
Yin Chan, B.S.
Research Associate II
626-256-HOPE, ext. 82823
Kelly Wong, B.S.
Research Associate I
626-256-HOPE, ext. 85061
2016, 2017 Ad Hoc Reviewer, BMCT Study Section, National Institutes of Health (NIH)
2016, Ad Hoc Reviewer, Molecular and Cellular Endocrinology Study Section, NIH
2008-2012, Member, Molecular and Cellular Endocrinology Study Section, NIH
2010, Member, Breast Cancer and the Environment Study Section, NIEHS
2008-2012, Member, Molecular and Cellular Endocrinology Study Section, NIH
2006, Programmatic reviewer, Department of Defense Breast Cancer Research Program
2004, Grant Applications Reviewer, Botanical Center, NIH
2003-2005, Member, Tumor Cell Biology Study Section, NIH
2002-2003, Member, Metabolic Pathology Study Section, NIH
2002, Corresponding Editor, The Journal of Steroid Biochemistry and Molecular Biology
2000, Member, Special Emphasis Panels, NIH
2000, Member, Special Emphasis Panels, NIH
2000-2001, Chair, Student Research Committee, American Heart Association, Western States Affiliate
1999-2000, Member, Study Section for Insight Award for Breast Cancer, NIH
1998-2002, Member, Research Committee, American Heart Association, Western States Affiliate
1998-1999, Member, U.S. Environmental Protection Agency, Endocrine Disruptor Study Section
1996-1998, 2001-2003, 2005, Member, Study Sections of the US Army Breast Cancer Research Program
1996-2000, Member, Reproductive Endocrinology Study Section, NIH
2023 American Association for the Advancement of Science (AAAS) Fellow
2021 Walk for Hope Medical Honoree
2019-2022 Strategy Advisor for the Calif. Breast Cancer Res. Program on Program Initiatives Round 3
2018 Invited speaker of 2018 Taipei International Breast Cancer Symposium, Taipei, Taiwan
2018 Invited speaker of the 4th Congress on Steroid Research, Seoul, Korea
2017 Lester M. and Irene C. Finkelstein Endowed Chair in Biology
2016 Keynote speaker of the 19th Congress of the International Society for Mushroom Science, Amsterdam, Netherlands
2015 Keynote speaker of the 20th Taiwan Joint Cancer Conference, Taiwan
2015 Invited member of the International Chinese Medicine Consortium, NCI
2012 City of Hope Portrait Gallery of Scientific Achievement
2012 Keynote speaker of the 18th Congress of the Int Soc for Mushroom Science, Beijing, China
2012 Invited speaker, 2012 International Symposium on Clinical and Translational Cancer Research, Kaohsiung, Taiwan
2011 Member of the National Breast Cancer Coalition’s Summit on Prevention of Breast Cancer
2011 Keynote speaker of the 2nd Iberic meeting on Medicinal Chemistry, Porto, Portugal
2009 Keynote speaker of the 5th International Medicinal Mushroom Conference
2007 Featured Researcher of the Calif. Breast Cancer Res. Program
2007 Recipient of the Gallery of Achievement Award for Science, City of Hope
2007 NCI/OCCAM Monthly Lecture Series presentation: Breast Cancer Prevention with Anti-aromatase Phytochemicals in Grapes and Mushroom
2005-2007 Chair (2007) and vice Chair (2005) of the Gordon Research Conference on “Hormone Action in Development and Cancer.”
Information listed here is obtained from PubMed, a public database. City of Hope is not responsible for its accuracy. Selected Peer-reviewed Publications (Selected from 266 peer reviewed publications)
Yoshitake R, Chang G, Saeki K, Ha D, Wu X, Wang J, Chen S. Single-cell transcriptomics identifies heterogeneity of mouse mammary gland fibroblasts with distinct functions, estrogen responses, differentiation processes, and crosstalks with epithelium. Frontiers in Cell and Developmental Biology, 10: 850568, 2022. PubMed PMID: 35300413; PubMed Central PMCID: PMC8923650
Mori H, Saeki K, Chang G, Wang J, Wu X, Hsu PY, Kanaya N, Wang X, Somlo G, Nakamura M, Bild A, Chen S. Influence of estrogen treatment on ESR1+ and ESR1- cells in ER+ breast cancer: Insights from single-cell analysis of patient-derived xenograft models. Cancers (Basel), 13 (24): 6375, 2021. PubMed PMID: 34944995; PubMed Central PMCID: PMC8699443
Wang Y, Chen S. TXNIP links anticipatory unfolded protein responses to estrogen reprogramming glucose metabolism in breast cancer cells. Endocrinology, 163 (1): bqab212, 2022. PubMed PMID: 34614512
Wang SF, Chang YL, Tzeng YD, Wu CL, Wang YZ, Tseng LM, Chen S, Lee HC. Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling. Cancer Lett. 523: 82-99, 2021. PubMed PMID: 34610415
Augusto TV, Amaral C, Wang Y, Chen S, Almeida CF, Teixeira N, Correia-da-Silva G. Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression. Breast Cancer Res Treat. 190(2): 227-240, 2021. PubMed PMID: 34498152
Wang X, Ha D, Yoshitake R, Chan YS, Sadava D, Chen S. Exploring the biologial activity and mechanism of xenoestrogens and phytoestrogens in cancers: Emerging methods and concepts. Int J Mol Sci. 22(16): 8798, 2021. PubMed PMID: 34445499; PubMed Central PMCID: PMC8395949
Ding YC, Hurley S, Park JS, Steele L, Rakoff M, Zhu Y, Zhao J, LaBarge M, Bernstein L, Chen S, Reyolds P, Neuhausen SL. Methylation biomarkers of polybrominated diphenyl ethers (PBDEs) and association with breast cancer risk at the time of menopause. Environ Int. 156: 106772, 2021. PubMed PMID: 344425644
Wang X, Ha D, Yoshitake R, Chen S. White button mushroom interrupts tissue AR-mediated TMPRSS2 expression and attenuates pro-inflammatory cytokines in C57BL/6 mice. NPJ Sci Food. 5(1): 20, 2021. PubMed PMID: 34341347; PubMed Central PMCID: PMC8329194
Saeki K, Chang G, Kanaya N, Wu X, Wang J, Bernal L, Ha D, Neuhausen S, Chen S. Mammary cell gene expression atlas links epithelial cell remodeling events to breast carcinogenesis. Commun Biol. 4(1): 892, 2021. PubMed PMID: 34079055; PubMed Central PMCID: PMC8172904
Saghaeidehkordi A, Chen S, Yang S, Kuar K. Evaluation of a keratin 1 targeting peptide-doxorubicin conjugate in a mouse model of triple-negative breast cancer. Pharmaceutics, 13(5): 661, 2021. PubMed PMID: 34063098; PubMed Central PMCID: PMC8148172
Rooney J, Ryan N, Liu J, Houtman R, van Beuningen R, Hsieh J, Chang G, Chen S, Corton C. A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor ɑ in an MCF-⁊ Microarray Compendium. Chem Res Toxicol. 34(2):313-329, 2021. PubMed PMID: 33405908
Wang X, Ha D, Mori H, Chen S. White button mushroom (Agaricus bisporus) disrupts androgen receptor signaling in human prostate cancer cells and patient-derived xenograft. J Nutr Biochem. 89:108580, 2021. PubMed PMID: 33388344; PubMed Central PMCID: PMC8542389
Barnard L, Schiffer L, Louw du-Toit R, Tamblyn J, Chen S, Africander D, Arlt W, Foster P, Storbeck K. 11-Oxygenated Estrogens Are a Novel Class of Human Estrogens but Do not Contribute to the Circulating Estrogen Pool. Endrocrinology. 162(3): bqaa231, 2021. PubMed PMID: 33340399; PubMed Central PMCID: PMC7814299
Wang X, Petrossian K, Huang M, Saeki K, Kanaya N, Chang G, Somlo G, Chen S. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer. J Steroid Biochem Mol Biol. 206: 105791, 2021. PubMed PMID: 33271252; PubMed Central PMCID: PMC8820229
Wang Y, Tzeng Y, Chang G, Wang X, Chen S. Amphiregulin retains ERɑ expression in acquired aromatase inhibitor resistant breast cancer cells. Endocr Relat Cancer. doi:10.1530/ERC-20-0258. 2020. PubMed PMID: 33112819; PubMed Central PMCID: PMC7665895
Wang S, Chen S, Tseng L, Lee H. Role of the mitochondrial stress response in human cancer progression. Exp Biol Med (Maywood). doi: 10.1177/1535370220920558. Epub 2020. PubMed PMID: 32326760; PubMed Central PMCID: PMC7268930
Bahrami N, Chang G, Kanaya N, Sauer T, Park D, Loeng M, Gravdehaug B, Chen S, Geisler J. Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane. J Steroid Biochem Mol Biol. doi: 10.1016/j.jsbmb.2020.105641. Epub 2020. PubMed PMID: 32151708
Chang G, Saeki K, Mori H, Chen S. Environmental Carcinogenesis at the Single Cell Level. Cancer Epidemoiol Biomarkers & Prevention. pii: cebp.1364.2019. doi: 10.1158/1055-9965.EPI-19-1364. [Epub ahead of print] 2020. PubMed PMID: 32132147; PubMed Central PMCID: PMC7483229
Ziaei E, Saghaeidehkordi A, Dill C, Maslennikov I, Chen S, Kuar K. Targeting triple negative breast cancer cells with novel cytotoxic peptide-doxorubicin conjugates. Bioconjug Chem. 30 (12): 3098-3106, 2019. PubMed PMID: 31715102; PubMed Central PMCID: PMC7965737
Kanaya N, Chang G, Wu X, Saeki K, Bernal L, Shim HJ, Wang J, Warden C, Yamamoto T, Li J, Park JS, Synold T, Vonderfecht S, Rakoff M, Neuhausen SL, Chen S. Single-cell RNA-sequencing analysis of estrogen- and endocrine-disrupting chemical-induced reorganization of mouse mammary gland. Commun Biol. 2019 Nov 5; 2: 406. Doi: 10. 1038/s42003-019-0618-9. eCollection 2019. PubMed PMID: 31701034; PubMed Central PMCID: PMC6831695
Zhang S, Sugawara Y, Chen S, Beelman RB, Tsuduki T, Tomata Y, Matsuyama S, Tsuji I. Mushroom consumption and incident risk of prostate cancer in Japan: A pooled analysis of the Miyagi Cohort Study and the Ohsaki Cohort Study. Int J Cancer. 2019 Sep. 4. Doi: 10.1002/ijc.32591 [Epub ahead of print]. 2019. PubMed PMID: 31486077; PubMed Central PMCID: PMC7154543
Terry MB, Michels KB, Brody JG, Byrne C, Chen S, Jerry DJ, Malecki KMC, Martin MB, Miller RL, Neuhausen SL, Silk K, Trentham-Dietz A. Breast Cancer and the Environment Research Program (BCERP). Environmental exposures during windows of susceptibility for breast cancer: a framework for prevention research. Breast Cancer Res. 21 (1): 96 doi: 10.1186/s13058-019-1168-2, 2019. PubMed PMID: 31429809; PubMed Central PMCID: PMC6701090
Kanaya N, Bernal L, Chang G, Yamamoto T, Nguyen D, Wang YZ, Park JS, Warden C, Wang J, Wu X, Synold T, Rakoff M, Neuhausen SL, Chen S. Molecular mechanisms of polybrominated diphenyl ethers (BDE-47, -100, -153) in human breast cancer cells and patient-derived xenografts. Toxicol Sci, 169 (2): 380-398, 2019. PubMed PMID: 30796839; PubMed Central PMCID: PMC6542340
Yamamoto T, Kanaya N, Somlo G, Chen S. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer. Breast Cancer Res Treat, Jan 3 doi: 10. 1007/s 10549-018-05104-9. [Epub ahead of print], 2019. PubMed PMID: 30607633; PubMed Central PMCID: PMC6452902
For my complete list of published works, see my bibliography: https://www.ncbi.nlm.nih.gov/pubmed?cmd=Link&LinkName=pubmed_pubmed&from_uid=28174265